Your browser doesn't support javascript.
loading
Serum amyloid A1 is upregulated in human glioblastoma.
Knebel, Franciele Hinterholz; Uno, Miyuki; Galatro, Thais F; Bellé, Luziane Potrich; Oba-Shinjo, Sueli Mieko; Marie, Suely Kazue N; Campa, Ana.
Afiliação
  • Knebel FH; Department of Clinical Chemistry, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, São Paulo, Brazil. fhknebel@usp.br.
  • Uno M; Department of Neurology, School of Medicine, University of São Paulo, São Paulo, São Paulo, Brazil.
  • Galatro TF; Center for Translational Research in Oncology, Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, São Paulo, Brazil.
  • Bellé LP; Department of Neurology, School of Medicine, University of São Paulo, São Paulo, São Paulo, Brazil.
  • Oba-Shinjo SM; Department of Clinical Chemistry, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, São Paulo, Brazil.
  • Marie SKN; Department of Neurology, School of Medicine, University of São Paulo, São Paulo, São Paulo, Brazil.
  • Campa A; Center for Translational Research in Oncology, Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, São Paulo, Brazil.
J Neurooncol ; 132(3): 383-391, 2017 05.
Article em En | MEDLINE | ID: mdl-28283801
Serum amyloid A1 (SAA1) is a sensitive acute phase reactant primarily produced by the liver in response to acute inflammation. We have recently shown that SAA affects proliferation, migration, and invasion of glioblastoma cell lines, which suggest its participation in the malignant process. Consistently, levels of SAA have been used as a non-invasive biomarker for the prognosis of many cancers. In this study, we aimed to investigate SAA serum levels and expression of SAA genes in human astrocytomas tissues. Serum and tissue samples were obtained from patients with astrocytoma grades I to III and glioblastoma (GBM or grade IV). Levels of circulating SAA were significantly higher in the serum of patients with AGII-IV when compared to non-neoplastic samples derived from non-neoplastic patients (NN) (p > 0.0001). Quantitative real time PCR (qRT-PCR) of 148 astrocytomas samples (grades I-IV) showed that SAA1 mRNA was significantly higher in GBM when compared to AGI-III and NN samples (p < 0.0001). Immunohistochemistry analysis revealed cytoplasmic positivity for SAA in GBM. There was no correlation of SAA1 with clinical end-point of overall survival among GBM patients. However, it was found a positive correlation between SAA1 and genes involved in tumor progression, such as: HIF1A (r = 0.50; p < 0.00001), CD163 (r = 0.52; p < 0.00001), CXCR4 (r = 0.42; p < 0.00001) and CXCR7 (r = 0.33; p = 0.002). In conclusions, we show that astrocytoma patients have increased levels of serum SAA and SAA1 is expressed and secreted in GBM, and its co-expression with tumor-related genes supports its involvement in GBM angiogenesis and progression.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Astrocitoma / Neoplasias Encefálicas / Proteína Amiloide A Sérica / Biomarcadores Tumorais / Glioblastoma Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Neurooncol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Astrocitoma / Neoplasias Encefálicas / Proteína Amiloide A Sérica / Biomarcadores Tumorais / Glioblastoma Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Neurooncol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos